Growth Metrics

Adma Biologics (ADMA) Other Non-Current Liabilities (2016 - 2025)

Historic Other Non-Current Liabilities for Adma Biologics (ADMA) over the last 14 years, with Q3 2025 value amounting to $90000.0.

  • Adma Biologics' Other Non-Current Liabilities fell 7600.0% to $90000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $90000.0, marking a year-over-year decrease of 7600.0%. This contributed to the annual value of $360000.0 for FY2024, which is 1408.11% down from last year.
  • Latest data reveals that Adma Biologics reported Other Non-Current Liabilities of $90000.0 as of Q3 2025, which was down 7600.0% from $2000.0 recorded in Q2 2025.
  • Adma Biologics' 5-year Other Non-Current Liabilities high stood at $789534.0 for Q2 2021, and its period low was $2000.0 during Q1 2025.
  • Over the past 5 years, Adma Biologics' median Other Non-Current Liabilities value was $385628.0 (recorded in 2022), while the average stood at $385134.0.
  • In the last 5 years, Adma Biologics' Other Non-Current Liabilities surged by 82101.52% in 2021 and then plummeted by 9950.62% in 2025.
  • Over the past 5 years, Adma Biologics' Other Non-Current Liabilities (Quarter) stood at $397351.0 in 2021, then dropped by 11.92% to $350000.0 in 2022, then increased by 19.71% to $419000.0 in 2023, then fell by 14.08% to $360000.0 in 2024, then crashed by 75.0% to $90000.0 in 2025.
  • Its Other Non-Current Liabilities was $90000.0 in Q3 2025, compared to $2000.0 in Q2 2025 and $2000.0 in Q1 2025.